RT Book, Section A1 Garvey, W. Timothy A1 Mechanick, Jeffrey I. A2 Fuster, Valentin A2 Narula, Jagat A2 Vaishnava, Prashant A2 Leon, Martin B. A2 Callans, David J. A2 Rumsfeld, John A2 Poppas, Athena SR Print(0) ID 1202441966 T1 Cardiometabolic Disease: Insulin Resistance, Obesity, and the Metabolic Syndrome T2 Fuster and Hurst's The Heart, 15e YR 2022 FD 2022 PB McGraw-Hill Education PP New York, NY SN 9781264257560 LK accesscardiology.mhmedical.com/content.aspx?aid=1202441966 RD 2023/12/06 AB Chapter SummaryThis chapter discusses the pathophysiology and treatment of cardiometabolic disease and obesity. Insulin resistance is at the core of the pathophysiology of cardiometabolic disease and can give rise to metabolic syndrome, prediabetes, and non-alcoholic fatty liver disease (NAFLD) (see Fuster and Hurst’s Central Illustration). Patients with insulin resistance, metabolic syndrome, and/or prediabetes have accelerated atherogenesis and increased risk for cardiovascular disease (CVD). Prediabetes and NAFLD can progress to type 2 diabetes and non-alcoholic steatohepatitis (NASH), respectively; these conditions further amplify the progression of vascular disease and risk of CVD events. Obesity can exacerbate insulin resistance and promote cardiometabolic disease progression, but it can also exist independent of cardiometabolic disease. In the prevention and treatment of cardiometabolic disease, intervention should be early and encompass metabolic and vascular outcomes. Healthy meal plans, aerobic and resistance exercise, and aggressive surveillance and management of CVD risk factors are all warranted. A chronic care model for cardiometabolic disease should be an integral component of health-care systems.